Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Ottmann

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
The Lancet. Haematology|December 4, 2018
Tyrosine kinase inhibitor therapy or transplant in children with Philadelphia chromosome-positive acute lymphoblastic leukaemia: striking the balanceOliver Ottmann
Antibodies (Basel, Switzerland)|April 30, 2021
Tinkering under the Hood: Metabolic Optimisation of CAR-T Cell TherapyYasmin Jenkins, Joanna Zabkiewicz, Oliver Ottmann, et al.
Leukemia & Lymphoma|September 14, 2004
Constitutive NF-kappab/Rel activation in philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL)Gerd Munzert, Dieter Kirchner, Oliver Ottmann, et al.
Experimental Hematology|June 28, 2003
Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activationDieter Kirchner, Justus Duyster, Oliver Ottmann, et al.
Genes & Cancer|March 26, 2016
BCR: a new target in resistance mediated by BCR/ABL-315I?Isabella Haberbosch, Anahita Rafiei, Claudia Oancea, et al.
Advances in Therapy|October 6, 2019
Clinicians' Perspectives on Cure in Adult Patients with Acute Lymphoblastic Leukemia with Minimal Residual Disease: A Delphi StudyWendy Gidman, Shweta Shah, Lirong Zhang, et al.
Leukemia Research|September 29, 2007
Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategyIman Jilani, Hagop Kantarjian, Mercedes Gorre, et al.
Cancer|March 24, 2010
Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intoleranceHagop Kantarjian, Phillipp le Coutre, Jorge Cortes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemiasJürgen Krauter, Kerstin Gorlich, Oliver Ottmann, et al.
Leukemia Research|December 25, 2007
An immunological method for the detection of BCR-ABL fusion protein and monitoring its activationIman Jilani, Hagop Kantarjian, Homan Faraji, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
The Lancet. Haematology|December 4, 2018
Tyrosine kinase inhibitor therapy or transplant in children with Philadelphia chromosome-positive acute lymphoblastic leukaemia: striking the balanceOliver Ottmann
Antibodies (Basel, Switzerland)|April 30, 2021
Tinkering under the Hood: Metabolic Optimisation of CAR-T Cell TherapyYasmin Jenkins, Joanna Zabkiewicz, Oliver Ottmann, et al.
Leukemia & Lymphoma|September 14, 2004
Constitutive NF-kappab/Rel activation in philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL)Gerd Munzert, Dieter Kirchner, Oliver Ottmann, et al.
Experimental Hematology|June 28, 2003
Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activationDieter Kirchner, Justus Duyster, Oliver Ottmann, et al.
Genes & Cancer|March 26, 2016
BCR: a new target in resistance mediated by BCR/ABL-315I?Isabella Haberbosch, Anahita Rafiei, Claudia Oancea, et al.
Advances in Therapy|October 6, 2019
Clinicians' Perspectives on Cure in Adult Patients with Acute Lymphoblastic Leukemia with Minimal Residual Disease: A Delphi StudyWendy Gidman, Shweta Shah, Lirong Zhang, et al.
Leukemia Research|September 29, 2007
Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategyIman Jilani, Hagop Kantarjian, Mercedes Gorre, et al.
Cancer|March 24, 2010
Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intoleranceHagop Kantarjian, Phillipp le Coutre, Jorge Cortes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemiasJürgen Krauter, Kerstin Gorlich, Oliver Ottmann, et al.
Leukemia Research|December 25, 2007
An immunological method for the detection of BCR-ABL fusion protein and monitoring its activationIman Jilani, Hagop Kantarjian, Homan Faraji, et al.
Pageof 6